National and international MM guidelines

Evidence-based clinical guidelines are designed to consolidate practice and help improve the quality of care
of people with MM. A number of national and international guidelines have been developed which are listed below.

Please check back here as we will be periodically updating this page as new evidence becomes
available and new therapeutics are developed.

Please note that this is a selection of the guidelines and not an exhaustive list. This overview is provided for
information purposes only. Please consult the guidelines directly for complete information.

Overview of MM guidelines

ASCO/CCO: The joint ASCO and CCO clinical practice guidelines provide evidence-based recommendations on the treatment of MM

EHA-ESMO: The EHA-ESMO Clinical Practice Guidelines provide recommendations on the management of both NDMM and RRMM

EMN: The EMN guidelines cover transplant and novel cellular therapies with the aim of harmonizing treatment selection in MM

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®):  NCCN Guidelines® focus on the diagnosis, workup and management of MM 

IMWG: The IMWG is an international society with the mission to provide scientifically validated consensus guidelines for the global multiple myeloma community


ASCO, American Society of Clinical Oncology; CCO, Cancer Care Ontario; EHA, European Hematology Association; EMN, European Myeloma Network; ESMO, European Society for Medical Oncology; IMWG, International Myeloma Working Group; MM, multiple myeloma; NCCN, National Comprehensive Cancer Network; NDMM, newly diagnosed MM; RRMM, relapsed/refractory MM.